OBJECTIVE: To assess the distribution of bacterial species and antimicrobial resistance in an ICU during long-term use of selective digestive decontamination (SDD) in the context of national reference data. DESIGN AND SETTING: Five-year prospective observational study in a 24-bed interdisciplinary surgical ICU of a university hospital (study ICU) participating in the project "Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units" (SARI; reference ICUs). PATIENTS: Resistance data were obtained from all patients; patients intubated for at least 2 days received SDD (colistin, tobramycin, amphotericin B). INTERVENTIONS AND MEASUREMENTS: SDD was performed in 1,913 of 7,270 patients. Antimicrobial resistance was examined in 4,597 (study ICU) and 46,346 (reference ICUs) isolates. RESULTS: Methicillin-resistant Staphylococcus aureus (MRSA) remained stable (2.76 and 2.58 isolates/1000 patient days) in the study ICU; this was below the German average (4.26 isolates/1000 patient days). Aminoglycoside- and betalactam-resistant Gram-negative rods did not increase during SDD use. Aminoglycoside resistance of Pseudomonas aeruginosa was 50% below the mean value of SARI (0.24 vs. 0.52 isolates/1,000 patient days). The relative frequency of enterococci and coagulase-negative staphylococci (CNS) was higher than in the SARI ICUs (23.2% vs. 17.3%, and 25.0% vs. 20.6%, respectively). CONCLUSION: Routine 5-year-use of SDD was not associated with increased antimicrobial resistance in our ICU with low baseline resistance rates. Vigorous surveillance and control measures to search and destroy MRSA were considered a mandatory component of the SDD program. The relative increase in enterococci and CNS is of concern requiring further investigation.
OBJECTIVE: To assess the distribution of bacterial species and antimicrobial resistance in an ICU during long-term use of selective digestive decontamination (SDD) in the context of national reference data. DESIGN AND SETTING: Five-year prospective observational study in a 24-bed interdisciplinary surgical ICU of a university hospital (study ICU) participating in the project "Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units" (SARI; reference ICUs). PATIENTS: Resistance data were obtained from all patients; patients intubated for at least 2 days received SDD (colistin, tobramycin, amphotericin B). INTERVENTIONS AND MEASUREMENTS: SDD was performed in 1,913 of 7,270 patients. Antimicrobial resistance was examined in 4,597 (study ICU) and 46,346 (reference ICUs) isolates. RESULTS: Methicillin-resistant Staphylococcus aureus (MRSA) remained stable (2.76 and 2.58 isolates/1000 patient days) in the study ICU; this was below the German average (4.26 isolates/1000 patient days). Aminoglycoside- and betalactam-resistant Gram-negative rods did not increase during SDD use. Aminoglycoside resistance of Pseudomonas aeruginosa was 50% below the mean value of SARI (0.24 vs. 0.52 isolates/1,000 patient days). The relative frequency of enterococci and coagulase-negative staphylococci (CNS) was higher than in the SARI ICUs (23.2% vs. 17.3%, and 25.0% vs. 20.6%, respectively). CONCLUSION: Routine 5-year-use of SDD was not associated with increased antimicrobial resistance in our ICU with low baseline resistance rates. Vigorous surveillance and control measures to search and destroy MRSA were considered a mandatory component of the SDD program. The relative increase in enterococci and CNS is of concern requiring further investigation.
Authors: Carlene A Muto; John A Jernigan; Belinda E Ostrowsky; Hervé M Richet; William R Jarvis; John M Boyce; Barry M Farr Journal: Infect Control Hosp Epidemiol Date: 2003-05 Impact factor: 3.254
Authors: Miguel A de La Cal; Enrique Cerdá; Paloma García-Hierro; Hendrick K F van Saene; Dulce Gómez-Santos; Eva Negro; José Angel Lorente Journal: Ann Surg Date: 2005-03 Impact factor: 12.969
Authors: M J Bonten; B J Kullberg; R van Dalen; A R Girbes; I M Hoepelman; W Hustinx; J W van der Meer; P Speelman; E E Stobberingh; H A Verbrugh; J Verhoef; J H Zwaveling Journal: J Antimicrob Chemother Date: 2000-09 Impact factor: 5.790
Authors: Wolfgang A Krueger; Alexandra Heininger; Béatrice Grabein; Klaus Unertl; Miguel Sánchez-García Journal: Antimicrob Agents Chemother Date: 2014-06 Impact factor: 5.191
Authors: María E Ochoa-Ardila; Ana García-Cañas; Karen Gómez-Mediavilla; Ana González-Torralba; Inmaculada Alía; Paloma García-Hierro; Nia Taylor; Hendrick K F van Saene; Miguel A de la Cal Journal: Intensive Care Med Date: 2011-07-19 Impact factor: 17.440
Authors: F M Brunkhorst; P Gastmeier; W Kern; W Krüger; K Mayer; A Weimann; T Welte; C Putensen; K Werdan; K Reinhart Journal: Internist (Berl) Date: 2010-07 Impact factor: 0.743
Authors: K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte Journal: Anaesthesist Date: 2010-04 Impact factor: 1.041
Authors: K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte Journal: Ger Med Sci Date: 2010-06-28
Authors: Guy J Oudhuis; Dennis C Bergmans; Tom Dormans; Jan-Harm Zwaveling; Alfons Kessels; Martin H Prins; Ellen E Stobberingh; Annelies Verbon Journal: Intensive Care Med Date: 2010-08-19 Impact factor: 17.440